PBAC's latest decision on Peginterferon beta-1a: Recommended with restriction (2014). Considered for First-line treatment of patients with remitting-relapsing multiple sclerosis.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2014
Submissions
1
2014 → 2014
Eligible population
Adults with clinically definite relapsing-remitting multiple sclerosis, with at least 2 documented attacks of neurological dysfunction in the preceding 2 years, who are ambulatory without assistance.
Therapy area
Neurology
Line of therapy
First-line
Evidence base
Meta-analysis
Primary endpoint
ORR
Pivotal trial size
1,909 patients
Key trials
ADVANCE, BRAVO
Comparator
interferon beta-1a
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis; no ICER calculated by design.